Home » Stocks » PAND

Pandion Therapeutics, Inc. (PAND)

Stock Price: $17.44 USD 0.16 (0.90%)
Updated November 30, 3:20 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 514.68M
Revenue (ttm) 7.56M
Net Income (ttm) n/a
Shares Out 29.52M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $17.44
Previous Close $17.28
Change ($) 0.16
Change (%) 0.90%
Day's Open 17.23
Day's Range 16.62 - 17.65
Day's Volume 21,254
52-Week Range 10.73 - 19.61

More Stats

Market Cap 514.68M
Enterprise Value 281.85M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 29.52M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 539,849
Short Ratio 6.30
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 68.12
PB Ratio 2.38
Revenue 7.56M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 232.83M
Net Cash / Share 7.89
Gross Margin 12.80%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(51.99% upside)
Current: $17.44
Target: 26.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit0.97-
Operating Income-22.22-11.05
Net Income-21.88-10.89
Shares Outstanding1.030.78
Earnings Per Share-25.00-17.00
Operating Cash Flow-13.43-10.61
Capital Expenditures-0.64-0.64
Free Cash Flow-14.06-11.24
Cash & Equivalents15.9710.17
Total Debt3.682.01
Net Cash / Debt12.298.16
Book Value-42.79-17.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pandion Therapeutics, Inc.
Country United States
CEO Rahul Kakkar

Stock Information

Ticker Symbol PAND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PAND
IPO Date July 17, 2020


Pandion Therapeutics, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.